Tori Spelling and Stella McDermott Join Forces with Arcutis Biotherapeutics for the *Free to Be Me* Campaign
1. Raising Awareness for Inflammatory Skin Conditions
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a prominent player in the biopharmaceutical sector focused on immuno-dermatology, recently unveiled its new awareness initiative, the *Free to Be Me* campaign. This campaign collaborates with actress Tori Spelling and her daughter, Stella McDermott, aiming to highlight the emotional and physical challenges faced by millions of Americans living with inflammatory skin conditions, such as atopic dermatitis and seborrheic dermatitis.
Approximately 36 million Americans are affected by these conditions, which can significantly impact quality of life. The campaign encourages individuals to consult with their healthcare providers about effective long-term treatment options, with a strong emphasis on the importance of personalized care.
2. Personal Stories that Resonate
In the campaign, Tori Spelling shares her personal journey of navigating chronic skin conditions alongside her daughter. Both Tori and Stella have battled eczema and seborrheic dermatitis, facing discomfort, sleep disturbances, and the emotional toll of these conditions. Their story underscores the broader impact that skin diseases can have on families, emphasizing that these challenges extend beyond the individual and can affect daily routines and family dynamics.
“Managing a chronic skin condition like eczema isn’t just about appearance — it’s about how you feel, how you show up for yourself and family, and how confidently you live your life,” Tori stated. Her endorsement of ZORYVE® (roflumilast), an FDA-approved topical treatment recommended by dermatologists, serves as a beacon of hope for those grappling with similar challenges.
3. The Science Behind ZORYVE
ZORYVE cream and foam, integral to the *Free to Be Me* campaign, are formulated to treat atopic dermatitis and seborrheic dermatitis, respectively. The cream is indicated for adults and children aged six and older, while the foam is designed for those nine and older. Clinical trials involving over 1,300 participants demonstrated that ZORYVE can significantly improve symptoms such as redness and itching, with one-third of users achieving clear skin in just four weeks.
Dr. Adam Friedman, a leading dermatologist at the George Washington University School of Medicine, commented on the necessity of effective treatment options for lifelong conditions like eczema. He noted that nonsteroidal topical treatments like ZORYVE provide patients and healthcare providers with confidence in managing these diseases safely and effectively over time.
4. Clinical Efficacy and Recognition
ZORYVE has received widespread acclaim and is now the number one prescribed topical therapy for various inflammatory skin conditions. Its clinical efficacy is supported by eight pivotal trials involving roughly 4,200 participants, showcasing its safety and tolerability profile. The most common side effects reported include headaches, nausea, and application site pain, which align with those observed in extensive clinical studies.
In addition to demonstrating clinical impact, ZORYVE has garnered industry recognition, including *Allure* magazine's "2025 Best of Beauty Breakthrough Award," and has been honored with the National Psoriasis Foundation’s Seal of Recognition. These accolades underscore Arcutis’ commitment to innovative solutions in dermatology.
5. Empowering Patients through the *Free to Be Me* Campaign
The *Free to Be Me* campaign not only shares stories of those living with inflammatory skin conditions but also empowers others to take charge of their skin health. By fostering open discussions with healthcare providers, patients can explore safe and effective treatment plans tailored to their needs.
Todd Edwards, Chief Commercial Officer of Arcutis, emphasized the importance of breaking the stigma surrounding visible skin conditions. He stated, “Tori Spelling’s willingness to speak openly helps empower others to take control of their skin health.”
6. Conclusion
Arcutis Biotherapeutics' *Free to Be Me* campaign represents a significant step forward in raising awareness and fostering discussions around inflammatory skin conditions. By partnering with well-known figures like Tori Spelling and her daughter, the campaign aims to encourage individuals to pursue effective long-term treatment options. As the healthcare landscape evolves, initiatives like this play a crucial role in connecting patients with the resources and support they need to manage chronic conditions effectively.
